Semaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, has seen explosive uptake due to its efficacy in glycemic control, weight loss and cardiometabolic risk reduction, driving multibillion-dollar revenues for originator companies Novo Nordisk (maker of semaglutide products Ozempic and Wegovy) and Eli Lilly (the pharma giant behind the tirzepatide products Mounjaro and Zepbound)
Robust clinical networks and crossborder research collaborations generate extensive realworld evidence, building clinician confidence
This is a professional led, self-paced online course that teaches you how to track macrosthe stress-free way
Caloric Intake Reduction Semaglutide works by slowing down the emptying of the stomach, which in turn decreases the rate at which calories are absorbed, resulting in an overall reduction in caloric intake
We just do not know. Hynes acknowledges the significant lack of data on the impact of GLP-1 RAs during pregnancy
Its good to stay mindful of maintaining balanced nutrition while also eating regular meals